T-cell lymphoma classification: Difference between revisions
No edit summary |
|||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{S.G.}} | {{CMG}}; {{AE}} {{S.G.}} | ||
==Overview== | ==Overview== | ||
There is no established system for the classification of [disease name]. | |||
OR | |||
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4]. | |||
OR | |||
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. | |||
[Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3]. | |||
OR | |||
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic. | |||
OR | |||
If the staging system involves specific and characteristic findings and features: | |||
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2]. | |||
OR | |||
The staging of [malignancy name] is based on the [staging system]. | |||
OR | |||
There is no established system for the staging of [malignancy name]. | |||
==Classification== | ==Classification== | ||
There is no established system for the classification of [disease name]. | |||
OR | |||
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: | |||
*[Group1] | |||
*[Group2] | |||
*[Group3] | |||
*[Group4] | |||
OR | |||
[Disease name] may be classified into [large number > 6] subtypes based on: | |||
*[Classification method 1] | |||
*[Classification method 2] | |||
*[Classification method 3] | |||
[Disease name] may be classified into several subtypes based on: | |||
*[Classification method 1] | |||
*[Classification method 2] | |||
*[Classification method 3] | |||
OR | |||
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic. | |||
OR | |||
'''If the staging system involves specific and characteristic findings and features:''' | |||
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2]. | |||
OR | |||
The staging of [malignancy name] is based on the [staging system]. | |||
OR | |||
There is no established system for the staging of [malignancy name]. | |||
===Updated World Health Organization Classification <ref>{{cite book | last = Swerdlow | first = Steven | title = WHO classification of tumours of haematopoietic and lymphoid tissues | publisher = International Agency for Research on Cancer | location = Lyon, France | year = 2008 | isbn = 9789283224310 }}</ref>=== | ===Updated World Health Organization Classification <ref>{{cite book | last = Swerdlow | first = Steven | title = WHO classification of tumours of haematopoietic and lymphoid tissues | publisher = International Agency for Research on Cancer | location = Lyon, France | year = 2008 | isbn = 9789283224310 }}</ref>=== |
Revision as of 21:28, 24 October 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
Overview
There is no established system for the classification of [disease name].
OR
[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].
OR
[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].
OR
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
Classification
There is no established system for the classification of [disease name].
OR
[Disease name] may be classified according to [classification method] into [number] subtypes/groups:
- [Group1]
- [Group2]
- [Group3]
- [Group4]
OR
[Disease name] may be classified into [large number > 6] subtypes based on:
- [Classification method 1]
- [Classification method 2]
- [Classification method 3]
[Disease name] may be classified into several subtypes based on:
- [Classification method 1]
- [Classification method 2]
- [Classification method 3]
OR
Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
OR
If the staging system involves specific and characteristic findings and features:
According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
OR
The staging of [malignancy name] is based on the [staging system].
OR
There is no established system for the staging of [malignancy name].
Updated World Health Organization Classification [1]
- T-cell and putative NK-cell neoplasms
- Precursor T-cell neoplasm: precursor T-acute lymphoblastic leukemia/LBL
- Peripheral T-cell lymphomas and NK-cell lymphomas
Peripheral T Cell Lymphoma
The WHO classification of T-cells NHL categorize them into Precursor T-cell neoplasm and Peripheral T-cell lymphomas/NK-cell neoplasms. The last one can be further subdivided into:
- T-cell prolymphocytic leukemia
- T-cell large granular lymphocytic leukemia
- Chronic lymphoproliferative disorder of NK cells
- Aggressive NK-cell leukemia
- EBV positive T-cell lymphoproliferative disorders of childhood
- Adult T-cell lymphoma/leukemia
- Extranodal T-/NK-cell lymphoma, nasal type
- Enteropathy-associated T-cell lymphoma
- Hepatosplenic T-cell lymphoma
- Subcutaneous panniculitis-like T-cell lymphoma
- Mycosis fungoides
- Sézary syndrome
- Primary cutaneous CD30 positive T-cell lymphoproliferative disorders
- Primary cutaneous peripheral T-cell lymphomas, rare subtypes
- Peripheral T-cell lymphoma, not otherwise characterized
- Angioimmunoblastic T-cell lymphoma
- Anaplastic large cell lymphoma, ALK positive
- Anaplastic large cell lymphoma, ALK negative
References
- ↑ Swerdlow, Steven (2008). WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer. ISBN 9789283224310.